Dr. Heffernan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
15 Santa Rosa St
San Luis Obispo, CA 93405Phone+1 805-541-2650Fax+1 805-541-4043
Summary
- Dr. Heffernan is an owner of San Luis Dermatology and the President of Heffernan Consulting LLC in San Luis Obispo, CA. As a researcher, Dr. Heffernan leads the US Dermatology operations for Probity Medical Research, a global consortium of clinical research sites. Dr. Heffernan has been the author of over 70 publications and textbook chapters. He has been an investigator on over 150 research protocols and he has given over 500 lectures around the globe.
Prior to returning to the practice of Dermatology, Dr. Heffernan was a Distinguished Medical Fellow and Senior Medical Director for Eli Lilly & Co. Previously, he served as Chairman of the Department of Dermatology at the Wright State University Boonshoft School of Medicine. He has held faculty appointments at the Uniformed Services University of the Health Sciences, Washington University School of Medicine, and the Indiana University School of Medicine.
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityResidency, Dermatology, 1994 - 1997
- University of MichiganInternship, Internal Medicine, 1993 - 1994
- University of Michigan Medical SchoolClass of 1993
- University of Notre DameBS, Preprofessional Studies, 1985 - 1989
- University of Notre DameBS, 1985 - 1989
Certifications & Licensure
- CA State Medical License 2012 - 2026
- FL State Medical License 2012 - 2016
- IN State Medical License 2013 - 2015
- MO State Medical License 2009 - 2015
- OH State Medical License 1998 - 2010
- MI State Medical License 1993 - 1994
- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Scholars Circle Dermatology Foundation, 2004
- Teacher of the Year-Dermatology Washington University School of Medicine, 2004-2005
- Member American Medical Association/GlaxoSmithKline Emerging Leaders Development Program, 2001
- Join now to see all
Clinical Trials
- Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus Start of enrollment: 2005 Jan 01
- Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis Start of enrollment: 2009 May 01
Publications & Presentations
PubMed
- 171 citationsEffect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure: The PACT-HF Randomized Clinical Trial.Harriette G.C. Van Spall, Shun Fu Lee, Feng Xie, Urun Erbas Oz, Richard Perez
JAMA. 2019-02-26 - 8 citationsLong-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI)Yaron Arbel, Dennis T. Ko, Andrew T. Yan, Warren J. Cantor, Akshay Bagai
The Canadian Journal of Cardiology. 2018-06-01 - 27 citationsKnowledge to action: Rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trial.Harriette G.C. Van Spall, Shun Fu Lee, Feng Xie, Dennis T. Ko, Lehana Thabane
American Heart Journal. 2017-12-01
Journal Articles
- Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naïve and TNF-IR Patients with Rheumatoid ArthritisGenovese MC, Braun DK, Erickson JS, Berclaz PY, Banerjee S, Heffernan MP, Carlier H, J Rheumatol., 1/15/2015
- A high level of clinical response is associated with improved patient-reported outcomes in psoriasis:analyses from a phase 2 study in patients treated with ixekizumabEdson-Heredia E, Banerjee S, Zhu B, Maeda-Chubachi T, Cameron GS, Shen W, Heffernan MP, et al., J Eur Acad Dermatol Venereol, 1/13/2015
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsGriffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickol..., Lancet, 1/8/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Off-Label Uses of Biologics.Heffernan MP, Utah Dermatology Society, Springdale, UT, 1/13/2010
- Practical Approaches to Patient Problems.Heffernan MP, AAD Annual Meeting, 1/1/2010
- Preliminary results on AAD formal leadership training programs for early career dermatologists.Morrison LK, Malone M, Carr D, Heffernan M, Marks V, American Academy of Dermatology Annual Meeting, 1/1/2010
- Join now to see all
Lectures
- Biologics 2015 and Beyond.18th Annual Winter Clinical Dermatology Meeting - 1/1/2015
- What the Sponsor Expects.Coastal Dermatology Meeting - 1/1/2015
- Biologics Beyond Psoriasis.Coastal Dermatology Meeting - 1/1/2015
- Join now to see all
Other
- Persistant Cutaneous Hyperpigmentation due to Hydroxychloroquinone One Year After Therapy Discontinuation.Morrison LK, Nordlund JJ, Heffernan MP, Dermatology Online Journal
1/1/2009 - Treatment Options for Atopic Dermatitis – 2007 Update.Heffernan MP, Houshmand E, US Special Populations: Pediatrics Review
1/1/2006 - Mycology #1.Anadkat MJ, Kanzler MH, Gorsulowsky DC, Heffernan MP, National Library of Dermatologic Teaching Slides #50
1/1/2004 - Join now to see all
External Links
- San Luis Dermatologyhttp://www.sanluisdermatology.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: